VIVEbiotech featured in PharmaSource for its innovative approach to lentiviral vector manufacturing
Natalia Elizalde, Chief Business Development Officer, shares expert insight on overcoming CGT manufacturing challenges.
We’re proud to see Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, featured in the latest PharmaSource article:
“7 Common Cell and Gene Therapy Manufacturing Challenges (and How to Solve Them)”
In the piece, Natalia highlights two major industry challenges and how VIVEbiotech is addressing them:
🔹 Cost Efficiency
“Since 2015, our goal has been to develop scalable, regulatory-compliant, and cost-effective lentiviral vector processes — focusing on high titers, purity, and transduction efficiency. Having multiple intermediate scales enables us to adapt production to each therapy’s specific needs.”
🔹 Capacity & Expertise
“In CGT, true capacity isn’t just about space or infrastructure — it’s about expertise. By specializing exclusively in lentiviral vectors, VIVEbiotech offers deep virology knowledge and a plug-and-play platform that helps accelerate clinical and commercial programs.”
🔗 Read the full article on PharmaSource:
7 Common Cell and Gene Therapy Manufacturing Challenges (and How to Solve Them)
At VIVEbiotech, we remain focused on solving CGT manufacturing complexities through innovation and precision.